FDA Expands Use of Zoryve to Include Young Children With Plaque Psoriasis

TUESDAY, July 14, 2026-- The U.S. Food and Drug Administration has approved an expanded indication for Zoryve (roflumilast) cream 0.3 percent for the topical treatment of plaque psoriasis in patients ages 2 years and older.Zoryve is a once-daily...